Oct 8, 2026 09:22AM
Sep 21, 2026 06:32AM
Jul 9, 2026 09:37AM
Apr 30, 2026 06:22AM
Apr 30, 2026 06:00AM
Feb 5, 2026 07:24AM
Jan 8, 2026 12:08PM The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
Nov 20, 2025 07:45AM
Jul 3, 2025 07:41AM
Jul 3, 2025 07:40AM
Jun 30, 2025 06:02AM
Jun 30, 2025 06:00AM
Jun 24, 2025 07:41AM
Jun 24, 2025 07:40AM OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteos
Jun 23, 2025 08:29PM
Jun 10, 2025 07:40AM
Jun 10, 2025 07:40AM
Jun 6, 2025 07:31AM
Jun 6, 2025 07:30AM
May 16, 2025 06:00AM
May 15, 2025 06:00AM OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
May 7, 2025 08:45AM
May 7, 2025 08:45AM
May 2, 2025 09:32AM
Apr 22, 2025 07:41AM
Apr 22, 2025 07:40AM
Apr 9, 2025 07:40AM
Apr 9, 2025 07:40AM OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
Apr 7, 2025 06:00AM
Apr 2, 2025 07:40AM
Mar 31, 2025 04:30PM
Mar 31, 2025 07:40AM
Mar 31, 2025 07:40AM
Mar 25, 2025 07:40AM
Mar 13, 2025 07:40AM OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
Mar 11, 2025 07:40AM
Feb 26, 2025 04:01PM
Feb 24, 2025 07:25AM
Feb 24, 2025 07:25AM
Feb 20, 2025 05:54AM
Feb 20, 2025 05:00AM
Feb 14, 2025 07:36AM OS Therapies (OSTX) Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
Feb 14, 2025 07:36AM
Feb 4, 2025 07:33AM
Feb 4, 2025 07:33AM
Jan 29, 2025 09:22AM
Jan 15, 2025 07:45AM
Jan 15, 2025 07:40AM
Jan 2, 2025 11:16AM OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Dec 31, 2024 03:38PM

334,272 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All